IS7804A - Indól nytsamleg við meðhöndlun á andrógen-viðtakatengdum sjúkdómum - Google Patents

Indól nytsamleg við meðhöndlun á andrógen-viðtakatengdum sjúkdómum

Info

Publication number
IS7804A
IS7804A IS7804A IS7804A IS7804A IS 7804 A IS7804 A IS 7804A IS 7804 A IS7804 A IS 7804A IS 7804 A IS7804 A IS 7804A IS 7804 A IS7804 A IS 7804A
Authority
IS
Iceland
Prior art keywords
indole
useful
treatment
related diseases
androgen receptor
Prior art date
Application number
IS7804A
Other languages
English (en)
Other versions
IS2700B (is
Inventor
Harold Han Hermkens Pedro
Thijs Stock Herman
Miranda Teerhuis Neeltje
Petrus Maria Lommerse Johannes
Van Der Louw Jaap
Original Assignee
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2003/050783 external-priority patent/WO2004041782A1/en
Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.
Publication of IS7804A publication Critical patent/IS7804A/is
Publication of IS2700B publication Critical patent/IS2700B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
IS7804A 2002-11-07 2005-04-18 Indól nytsamleg við meðhöndlun á andrógen-viðtaka tengdum sjúkdómum IS2700B (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42457902P 2002-11-07 2002-11-07
EP02079648 2002-11-07
PCT/EP2003/050783 WO2004041782A1 (en) 2002-11-07 2003-11-03 Indoles useful in the treatment of androgen-receptor related diseases
EP03810458A EP1585727B1 (en) 2002-11-07 2003-11-03 Indoles useful in the treatment of androgen-receptor related diseases

Publications (2)

Publication Number Publication Date
IS7804A true IS7804A (is) 2005-04-18
IS2700B IS2700B (is) 2010-11-15

Family

ID=32313841

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7804A IS2700B (is) 2002-11-07 2005-04-18 Indól nytsamleg við meðhöndlun á andrógen-viðtaka tengdum sjúkdómum

Country Status (15)

Country Link
US (2) US7795280B2 (is)
KR (1) KR20050072812A (is)
AR (1) AR042001A1 (is)
CL (1) CL2003002243A1 (is)
CO (1) CO5580758A2 (is)
DE (1) DE60332769D1 (is)
EC (1) ECSP055782A (is)
EG (1) EG24959A (is)
HR (1) HRP20050396A2 (is)
IS (1) IS2700B (is)
LV (1) LV13359B (is)
MX (1) MXPA05004929A (is)
NO (1) NO329778B1 (is)
PE (1) PE20040788A1 (is)
ZA (1) ZA200503559B (is)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200602317A (en) * 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
BRPI0706523A2 (pt) * 2006-01-13 2011-01-04 Wyeth Corp composto de fórmula i; composição farmacêutica; método de tratamento de distúrbios que estão relacionados com ou são afetados pela inibição da recaptação de norepinefrina, o receptor de 5-ht6 ou o receptor de 5-ht2a; método de tratamento de um distúrbio de aprendizado, de um distúrbio cognitivo, de um distúrbio de memória, de um distúrbio de personalidade, de um distúrbio comportamental, de um distúrbio de movimento, de um distúrbio neurodegenerativo, de abstinência de droga, de distúrbio de sono, de um distúrbio alimentar, de uma toxicidade de droga aguda, de um distúrbio cardiovascular, de uma disfunção sexual, de um distúrbio gastrintestinal, de um distúrbio genitourinário, de um distúrbio de dor, de um distúrbio nervoso ou de um distúrbio de sintoma vasomotor; método de tratamento de doença de alzheimer, de um distúrbio de deficiência da atenção, de esquizofrenia, de doença de parkinson, de discinésia tardia, de ataxia, de bradicinésia, de discinésias paroxìsmicas, de sìndrome da perna irrequieta, de tremor, de tremor essencial, de epilepsia, de apoplexia ou de trauma na cabeça; método de tratamento de doença arterial coronariana, de enfarte do miocárdio, de ataque isquêmico transitório, de angina, de fibrilação atrial, de agregação plaquetária, de risco de formação de coágulo sanguìneo, de sìndrome do intestino irritável, de constipação crÈnica, de doença do refluxo gastrintestinal, de dispepsia, de incontinência urinária por estresse ou de incontinência urinária de urgência; método de tratamento de depressão, de distúrbio compulsivo obsessivo, de tendência ao suicìdio, de distúrbio de ansiedade, de distúrbio bipolar, de distúrbio de pánico, de abstinência de nicotina, de abstinência de álcool, de abstinência de cocaìna, de abstinência de heroìna, de abstinência de anfetamina, de abstinência de drogas narcóticas, de insÈnia, de apnéia do sono, de narcolepsia, de distúrbio afetivo sanzonal, de sìndrome da perna irrequieta, de distúrbio de sono de turno de trabalho, de sìndrome da fase do sono retardada, de anorexia nervosa, de bulimia nervosa, de sìndrome do comer noturno, de superalimentação compulsiva, de sìndrome da fadiga crÈnica, de fibromialgia, de neuropatia de dor, de dor antinociceptiva, de sìndrome da dor crÈnica, de neuropatia diabética, de fogacho ou de suor noturno; e uso de um composto
DE102006014324B4 (de) * 2006-03-23 2009-01-08 Bayer Schering Pharma Aktiengesellschaft Inhibitoren der löslichen Adenylatzyklase
KR102881465B1 (ko) 2017-01-05 2025-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
CN112423844B (zh) 2018-07-04 2024-08-13 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
JOP20210218A1 (ar) 2019-02-12 2023-01-30 Radius Pharmaceuticals Inc عمليات ومركبات

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ179580A (en) 1974-12-30 1978-04-03 Mcneilab Inc 2-or 3-(w-tertiaryaminoalkyl)-thioindoles and the corresponding sulfinyl and sulfonyl analogs
US4059583A (en) * 1975-11-13 1977-11-22 Mcneil Laboratories, Incorporated Substituted indoles
JPS63313770A (ja) 1987-06-16 1988-12-21 Sumitomo Chem Co Ltd イサチン誘導体、その製造法およびそれを有効成分とする除草剤
ES2054784T3 (es) 1987-08-08 1994-08-16 Akzo Nv Un metodo para la fabricacion de un implante.
DE3924052A1 (de) 1989-07-21 1991-01-24 Bayer Ag N- (indol-6-yl)-heterocyclen
WO1991003585A1 (en) 1989-09-08 1991-03-21 Institute Of Textile Technology Method and apparatus for modifying spun textile yarn
FR2662713B1 (fr) * 1990-05-29 1994-04-08 Oreal Procede de teinture de fibres keratiniques avec un aminoindole associe a un derive quinonique.
US5938792A (en) * 1991-04-18 1999-08-17 L'oreal Process for dyeing keratinous fibers with aminoindoles and oxidation dye precursors at basic Ph's and dyeing agents
FR2675380A1 (fr) 1991-04-18 1992-10-23 Oreal Procede de teinture des fibres keratiniques avec des aminoindoles, a ph basique, compositions mises en óoeuvre et nouveaux composes.
GB9204365D0 (en) * 1992-02-28 1992-04-08 Pfizer Ltd Indoles
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
ATE275142T1 (de) 1996-11-25 2004-09-15 Procter & Gamble 2-imidazolinylaminoindol verbindungen als alpha-2 adrenoceptor agonisten
IL123813A0 (en) 1997-04-11 1998-10-30 Akzo Nobel Nv Drug delivery system for two or more active substances
US5969155A (en) * 1997-04-11 1999-10-19 The United States Of America As Represented By The Secretary Of The Army Conversion of trinitrotoluene into high value compounds
CA2322163A1 (en) 1998-02-25 1999-09-02 John Mckew Inhibitors of phospholipase a2
SK12742000A3 (sk) 1998-02-25 2001-05-10 Genetics Institute, Inc. Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie
GB9819033D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
TWI317634B (en) * 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
WO2003057669A1 (fr) 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Antagonistes du recepteur androgene
EP1501826B1 (en) 2002-02-01 2006-09-27 F. Hoffman-la Roche AG Substituted indoles as alpha-1 agonists
CA2523253C (en) * 2003-05-09 2010-06-22 F. Hoffmann-La Roche Ag Methyl indoles and methyl pyrrolopyridines as alpha-1 adrenergic agonists
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens

Also Published As

Publication number Publication date
DE60332769D1 (de) 2010-07-08
IS2700B (is) 2010-11-15
LV13359B (en) 2006-03-20
NO20052012L (no) 2005-05-26
ECSP055782A (es) 2005-08-11
PE20040788A1 (es) 2004-12-10
CO5580758A2 (es) 2005-11-30
US8124647B2 (en) 2012-02-28
US7795280B2 (en) 2010-09-14
HRP20050396A2 (en) 2005-06-30
US20060128722A1 (en) 2006-06-15
CL2003002243A1 (es) 2005-01-14
MXPA05004929A (es) 2005-08-18
US20110065768A1 (en) 2011-03-17
EG24959A (en) 2011-02-18
KR20050072812A (ko) 2005-07-12
ZA200503559B (en) 2006-08-30
HK1078875A1 (en) 2006-03-24
NO329778B1 (no) 2010-12-13
AR042001A1 (es) 2005-06-08

Similar Documents

Publication Publication Date Title
IS8127A (is) Aðferðir og samsetningar sem nýta ónæmistemprandiefnasambönd í meðferð og umönnun á krabba og öðrum sjúkdómum
NO20044054L (no) Administrering av midler for behandling av betennelse
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
DK1673104T4 (da) Fremføring af terapeutiske forbindelser til hjernen og andre væv
CL2003002417A1 (es) Tratamiento de tejido con celulas mesenquimales indifereenciadas
EP1530449A4 (en) Artificial cornea
IS7814A (is) Fenetanólamín afleiða í meðhöndlun á öndunarfærasjúkdómum.
DE60322582D1 (de) Oberflächenbehandlung von medizinischem gerät
EA200500098A1 (ru) Лекарственное средство и способ лечения патологического синдрома
NO20026008L (no) Fremgangsmåte for behandling av cardiovaskul¶re sykdommer
IS7444A (is) Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum
NO20045554L (no) Fremgangsmate for behandling av diabetes
ITMI20031797A1 (it) Procedimento e dispositivo per evitare spostamenti della
IS6137A (is) Meðhöndlun á hugsýkistruflunum
DK1553950T3 (da) Terapeutisk behandling
ITMI20010957A0 (it) Derivati dell'aoe-emodina e loro impiego nel trattamento di patologieneoplastiche
NO20050689L (no) Terapeutisk anvendelse
DE60326190D1 (de) des Körpers
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
NO20052814D0 (no) Cytomodulerende peptider for behandling av interstitielle cystitt
IS2700B (is) Indól nytsamleg við meðhöndlun á andrógen-viðtaka tengdum sjúkdómum
IS7868A (is) Notkun á kortkólíberín-úrókortín kerfi í meðferð á bólguvaldandi sjúkdómum.
ATA7862002A (de) Wasserauslaufbatterie
NO20022747L (no) Behandlingsstol